“Fortunately for everyone, clinics and labs around the world are researching the disease in an effort to either cure it or create a vaccine that provides immunity to the populace. One such effort is taking place at the Mayo Clinic in Minnesota, and according to Shams Charania of The Athletic, the NBA and its players are supporting it. The study, according to Charania, will focus on antibodies in recovered players to understand the prevalence of the disease in and around the NBA.”
“This is not the first such study that has been supported by the NBA. A number of NBA players that have recovered from the coronavirus, including Boston Celtics guard Marcus Smart, donated their blood for an experimental treatment for high-risk COVID-19 patients, according to Dr. Michael Joyner, a member of the leadership team of the National COVID-19 Convalescent Plasma Project.”
MAA COVID-19 INFORMATION DISCLAIMER:
The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service. The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.
The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via email or other communications.